LONRF2

Across TCGA pan-cancer cohorts, LONRF2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LONRF2 data layer compared with 21 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher LONRF2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LONRF2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CESC, UCEC, and SCLC are the cancer types where LONRF2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.068	0.830	<.001	30	view →
UCEC	DFS	Median	III,IV	1.000	0.540	.036	14	view →
SCLC	DFS	Median	All	0.164	0.625	.018	12	view →
HNSC	DFS	Median	II,III,IV	0.204	0.697	.005	12	view →
SKCM	OS	Median	All	0.376	0.787	.004	9	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LONRF2–CESC (OS)

Open the CESC breakdown →